Sign up
Pharma Capital

Faron Pharma chief "thrilled" at early cancer trial progress

Nine patients have been dosed so far with Clevegen, a new type of immune-oncology drug
Clinical trials esting
Faron has outlined plans to expand the phase I/II MATINS study of its Clevegen treatment

Faron Pharmaceuticals Oy (LON:FARN) shares shot higher on Friday as its chief executive Dr Markku Jalkanen said he is “thrilled” with the progress of the firm’s early-stage cancer clinical trial.

Faron has outlined plans to expand the phase I/II MATINS study of its Clevegen treatment in patients with CLEVER-1 positive cancer types.

It said it intends to keep the colorectal cancer expansion group open, enrolling patients while more data is generated.

And the company said it will approach the authorities to see if it can garner fast-track approval for the drug as a last-line treatment for those people who have exhausted all other options.

“On the basis of Clevegen's current safety profile and potential in patients who have exhausted by all other treatment options, the company believes it may seek initial regulatory approval supported by data from the expanding MATINS trial by 2022,” Faron told investors.

Nine patients have been dosed so far with Clevegen, a new type of immune-oncology drug.

The trial thus far has shown:

  • Clevegen well tolerated also at high doses
  • A consitent shift in immune cell profiles  
  • Anti-cancer responses continue

On the latter, two patients have benefited from receiving Clevegen.

A so-called partial responder with colorectal cancer has continued to see lung metastasis shrink. The person’s tumour load marker, which measures tumour mass, has also “normalised”.

A second person with colorectal cancer has seen a 40% decrease carcinogenic embryonal antigens, while the tumour has stabilised.

Partnering discussions for Clevegen are expected to be concluded sometime in the second half, Faron said.

Once it has tied up a deal, the company hopes to expand the clinical development of the promising drug to include the use of Clevegen in combination with other immunotherapies.

CEO Jalkanen told investors: “We are thrilled with the progress the MATINS study has made during the last few months.

“We believe we have the first macrophage immune checkpoint drug in clinical development promoting immune activation and are encouraged by the latest data indicating potential early efficacy and good tolerability.”

In morning trading, Faron shares topped the London market's gainers board, up 24% to 193p.

 -- Adds share price --

Ian_55ae0ddd437b7.jpg
Why Invest In Faron Pharmaceuticals Ltd? Read More Here

Register here to be notified of future FARN Company articles
View full FARN profile View Profile
View All

Related Articles

1550850611_CancerHeadline.jpg
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.